Compare Regeneron Pharmaceuticals Inc (REGN) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $745.9 (market cap $76.14B), while State Street SPDR S&P Homebuilders ETF trades at $95.99 (market cap $1.49B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 51.1× State Street SPDR S&P Homebuilders ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while State Street SPDR S&P Homebuilders ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| REGN | XHB | |
|---|---|---|
Market Cap | $76.14B | $1.49B |
Volume | 500,239 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $852.03 | $121.36 |
52-Week Low | $557.73 | $94.86 |
Typical Hold Time | 107 Days | 33 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
XHB (SPDR S&P Homebuilders ETF) trades at $94.89, down 2.55% amid broader housing sector pressure from rising mortgage rates. Technical indicators show bearish momentum with moving averages signaling sell pressure, though RSI suggests potential oversold conditions. Recent news highlights institutional interest with Greenland Capital's $17.33 million investment, while new housing legislation and mixed home sales data create uncertainty. The ETF's valuation metrics remain undisclosed in current data.
The housing ETF faces headwinds from 7% mortgage rates but benefits from structural demand and policy support. Near-term performance hinges on interest rate trends and housing market data, with current technical weakness offering potential entry points for long-term housing recovery bets. Key risks include prolonged high rates and economic slowdown impacting buyer affordability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
